This study tests a new drug called chiauranib for people with advanced solid malignant tumors, such as SCLC (small cell lung cancer), NSCLC (non-small cell lung cancer), and others. There are two phases: Phase 1b tests different doses to find a safe amount, while Phase 2 gives the recommended dose to all participants. Participants in Phase 1b will try different doses (35 mg, 50 mg, 65 mg) daily for a 34-day period, while Phase 2 participants will take it for continuous 28-day cycles. The study is open to adults with specific cancers who have tried other treatments that didn't work or where no standard treatment is available. People with certain health issues like uncontrolled heart problems or active infections can't join. Participants must use effective birth control during and after the study.

• The study involves daily medication for at least 28 days.
• Participants must be at least 18 years old and meet certain health criteria.
• Those in the study will need regular check-ups and monitoring.